[author: Sherri Oslick]

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Enzo Life Sciences Inc. v. Siemens Healthcare Diagnostics Inc.
1:12-cv-00505; filed April 20, 2012 in the District Court of Delaware

Infringement of U.S. Patent No. 7,064,197 ("System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids," issued June 20, 2006) based on Siemens' manufacture, use, and sale of nucleic acid array products.  View the complaint here.

Apotex, Inc. et al. v. Mylan Pharmaceuticals, Inc.
0:12-cv-60704; filed April 20, 2012 in the Southern District of Florida

• Plaintiffs:  Apotex, Inc.; Apotex Corp.
• Defendant:  Mylan Pharmaceuticals, Inc.

Apotex, Inc. et al. v. Pfizer, Inc. et al.
0:12-cv-60705; filed April 20, 2012 in the Southern District of Florida

• Plaintiffs:  Apotex, Inc.; Apotex Corp.
• Defendants:  Pfizer, Inc.; Greenstone LLC

Apotex, Inc. et al. v. Lupin Pharmaceuticals, Inc. et al.
0:12-cv-60708; filed April 20, 2012 in the Southern District of Florida

• Plaintiffs:  Apotex, Inc.; Apotex Corp.
• Defendants:  Lupin Pharmaceuticals, Inc.; Lupin Ltd.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 6,531,486 ("Pharmaceutical Compositions Comprising Quinapril Magnesium," issued March 11, 2003) based on defendants' manufacture of Pfizer's Accupril® and/or Accuretic® (quinapril hydrochloride  and quinapril hydrochloride plus hydrochlorothiazide, used to treat hypertension) or a generic version thereof.  View the Mylan complaint here.

Apotex, Inc. et al. v. UCB, Inc. et al.
0:12-cv-60706; filed April 20, 2012 in the Southern District of Florida

• Plaintiffs:  Apotex, Inc.; Apotex Corp.
• Defendants:  UCB, Inc.; Schwarz Pharma Inc.; Kremers Urban Pharmaceuticals, Inc.

Apotex, Inc. et al. v. Paddock Laboratories, Inc. et al.
0:12-cv-60707; filed April 20, 2012 in the Southern District of Florida

• Plaintiffs:  Apotex, Inc.; Apotex Corp.
• Defendants:  Paddock Laboratories, Inc.; Perrigo Company

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 6,767,556 ("Pharmaceutical Compositions Comprising Moexipril Magnesium" issued July 27, 2004) based on defendants' manufacture of UCB's Univasc® (moexipril, used to treat hypertension) or a generic version thereof.  View the UCB complaint here.

Genzyme Corp. v. Cobrek Pharmaceuticals, Inc.
1:12-cv-02937; filed April 20, 2012 in the Northern District of Illinois

Infringement of U.S. Patent No. 5,602,116 ("Method for Treating and Preventing Secondary Hyperparathyroidism," issued February 11, 1997) following a Paragraph IV certification as part of Cobrek's filing of an ANDA to manufacture a generic version of Genzyme's Hectorol® (doxercalciferol, used to treat secondary hyperparathyroidism in patients with chronic kidney disease).  View the complaint here.

Genzyme Corp. v. Invagen Pharmaceuticals, Inc.
1:12-cv-01931; filed April 19, 2012 in the Eastern District of New York

Infringement of U.S. Patent No. 5,667,775 ("Phosphate-Binding Polymers for Oral Administration," issued on September 16, 1997) following a Paragraph IV certification as part of Invagen's filing of an ANDA to manufacture a generic version of Genzyme's Renvela® (sevelamer carbonate, used for the control of serum phosphorus in patients with chronic kidney disease on dialysis).  View the complaint here.

Purdue Pharma L.P. et al. v. Watson Laboratories, Inc.
1:12-cv-03111; filed April 19, 2012 in the Southern District of New York

• Plaintiffs:  Purdue Pharma L.P.; Grunenenthal GmbH
• Defendant:  Watson Laboratories, Inc.

Infringement of U.S. Patent No. 8,114,383 ("Abuse-Proofed Dosage Form," issued February 14, 2012 following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.